Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •HIV positive
• •Presence of internal anal lesions with histologically confirmed high-grade squamous intraepithelial neoplasia with at least 1 positive margin
• •* No more than 3 lesions, each no more than 10 mm in diameter
• •No evidence of microscopic invasion in any anal biopsy specimens
• •No history of anal cancer
• •PATIENT CHARACTERISTICS:
• •Age
• •Over 18
• •Performance status
• •Karnofsky 70-100%
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Platelet count at least 50,000/mm\^3
• •CD4 count at least 50 cells/mm\^3
• •Hepatic
• •Not specified
• •Renal
• •Not specified
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No allergy to lidocaine
• •No anal insertions, including enemas or anal intercourse, for 24 hours before and at least 1 week after study treatment
• •No prior severe photosensitivity reaction
• •No active opportunistic infection
• •No concurrent neoplasia requiring cytotoxic therapy
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •Not specified
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •Not specified
• •Surgery
• •Not specified
• •Other
• •Must be on stable regimen of highly active antiretroviral therapy (HAART) for at least 12 weeks prior to study entry unless CD4 count \> 200/mm\^3 AND no plans to initiate HAART within the next 3 months
• •More than 14 days since prior acute treatment for an infection or other medical illness
• •No prior infrared coagulation for anal dysplasia